Prof. Carmelo Rizzari - The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients

1:02:15
 
공유
 

Manage episode 337376657 series 41876
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/JFN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimized use of asparaginase is a cornerstone of successful administration of multiagent chemotherapy in acute lymphoblastic leukemia (ALL) and has implications for patient outcomes across populations—are you prepared for the emergence of novel asparaginase formulations and the use of strategies that can help avoid treatment discontinuation? This MasterClass & Case Forum video presents an opportunity to understand and surmount the challenges associated with delivering effective ALL care with the asparaginase component of modern therapy. In this activity, an expert panel addresses topics ranging from current guidance on first- and second-line asparaginase options, monitoring and management of barriers such as asparaginase hypersensitivity, and therapeutic planning using available tools to maintain asparaginase exposure. Upon completion of this activity, participants should be better able to: Summarize comprehensive management recommendations for pediatric, AYA, and adult patients with ALL, including chemotherapy and asparaginase protocols, immunotherapy, and tyrosine kinase inhibitors; Cite the clinical impact of E coli asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations; Develop evidence-based treatment plans for asparaginase sequencing with E coli and Erwinia asparaginase, including recombinant formulations; and Manage E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.

909 에피소드